Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.

Slides:



Advertisements
Similar presentations
CQ Deng, PhD PPD Development Research Triangle Park, NC 27560
Advertisements

Agency for Healthcare Research and Quality (AHRQ)
Study Size Planning for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Research Study Designs
Designing Clinical Research Studies An overview S.F. O’Brien.
LSU-HSC School of Public Health Biostatistics 1 Statistical Core Didactic Introduction to Biostatistics Donald E. Mercante, PhD.
Analysis & Expressing Resultd in Clinical Trials Dr. Khalili.
Research in Abnormal Psychology
ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2009.
Concept of Measurement
Using Between-Subjects and Within-Subjects Experimental Designs
Fundamentals of Biostatistics Lecture 2 1.Clinical Trials 2.Validity/Reliability 3.Assessing Evidence.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Chapter 14 Inferential Data Analysis
Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C.
BC Jung A Brief Introduction to Epidemiology - XI (Epidemiologic Research Designs: Experimental/Interventional Studies) Betty C. Jung, RN, MPH, CHES.
Determining Sample Size
Chapter 1: Introduction to Statistics
Study Design. Study Designs Descriptive Studies Record events, observations or activities,documentaries No comparison group or intervention Describe.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
Research Design. Research is based on Scientific Method Propose a hypothesis that is testable Objective observations are collected Results are analyzed.
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
Chapter 2 Research in Abnormal Psychology. Slide 2 Research in Abnormal Psychology  Clinical researchers face certain challenges that make their investigations.
Control in Experimentation & Achieving Constancy Chapters 7 & 8.
© 2008 McGraw-Hill Higher Education The Statistical Imagination Chapter 10. Hypothesis Testing II: Single-Sample Hypothesis Tests: Establishing the Representativeness.
PTP 560 Research Methods Week 6 Thomas Ruediger, PT.
Tips for Researchers on Completing the Data Analysis Section of the IRB Application Don Allensworth-Davies, MSc Statistical Manager, Data Coordinating.
Consumer behavior studies1 CONSUMER BEHAVIOR STUDIES STATISTICAL ISSUES Ralph B. D’Agostino, Sr. Boston University Harvard Clinical Research Institute.
Copyright © 2013, 2009, and 2007, Pearson Education, Inc. Chapter 4 Gathering Data Section 4.3 Good and Poor Ways to Experiment.
Successful Concepts Study Rationale Literature Review Study Design Rationale for Intervention Eligibility Criteria Endpoint Measurement Tools.
Alec Walker September 2014 Core Characteristics of Randomized Clinical Trials.
Sample Size In Clinical Trials In The Name Of God Sample size in clinical trials.
Evaluating Impacts of MSP Grants Hilary Rhodes, PhD Ellen Bobronnikov February 22, 2010 Common Issues and Recommendations.
EXPERIMENTAL EPIDEMIOLOGY
How to Read Scientific Journal Articles
Introduction to the Statistical Analysis of the Clinical Trials
Introduction section of article
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
1 Updates on Regulatory Requirements for Missing Data Ferran Torres, MD, PhD Hospital Clinic Barcelona Universitat Autònoma de Barcelona.
Research Methods Objectives –Understanding sampling –Understanding different research designs –Understanding strengths and weaknesses of different designs.
One-Way Analysis of Covariance (ANCOVA)
Evaluating Impacts of MSP Grants Ellen Bobronnikov Hilary Rhodes January 11, 2010 Common Issues and Recommendations.
Establishing Efficacy through Randomized Controlled Clinical Trials Ernst R. Berndt, Ph.D. MIT and NBER.
Critical Appraisal (CA) I Prepared by Dr. Hoda Abd El Azim.
BC Jung A Brief Introduction to Epidemiology - XIII (Critiquing the Research: Statistical Considerations) Betty C. Jung, RN, MPH, CHES.
Evaluating Impacts of MSP Grants Ellen Bobronnikov January 6, 2009 Common Issues and Potential Solutions.
PTP 661 EVIDENCE ABOUT INTERVENTIONS CRITICALLY APPRAISE THE QUALITY AND APPLICABILITY OF AN INTERVENTION RESEARCH STUDY Min Huang, PT, PhD, NCS.
IMPORTANCE OF STATISTICS MR.CHITHRAVEL.V ASST.PROFESSOR ACN.
Evaluation Requirements for MSP and Characteristics of Designs to Estimate Impacts with Confidence Ellen Bobronnikov February 16, 2011.
European Patients’ Academy on Therapeutic Innovation The Purpose and Fundamentals of Statistics in Clinical Trials.
Introduction to statistics Definitions Why is statistics important?
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
Statistical Criteria for Establishing Safety and Efficacy of Allergenic Products Tammy Massie, PhD Mathematical Statistician Team Leader Bacterial, Parasitic.
CRITICAL APPARAISAL OF A PAPER ON THERAPY 421 CORSE EVIDENCE BASED MEDICINE (EBM)
Introduction to General Epidemiology (2) By: Dr. Khalid El Tohami.
STA248 week 121 Bootstrap Test for Pairs of Means of a Non-Normal Population – small samples Suppose X 1, …, X n are iid from some distribution independent.
CONFIDENTIAL © 2012 | 1 Writing a Statistical Analysis Plan DIA Medical Writing SIAC July 12, 2012 Peter Riebling, MS, RAC Associate Director, Regulatory.
Chapter 12 Quantitative Questions and Procedures.
CLINICAL PROTOCOL DEVELOPMENT
Francis KL Chan Department of Medicine & Therapeutics CUHK
Randomized Trials: A Brief Overview
Critical Reading of Clinical Study Results
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
Joanna Romaniuk Quanticate, Warsaw, Poland
Intent-to-treat Analysis of Randomized Clinical Trials.
Understanding Statistical Inferences
How Should We Select and Define Trial Estimands
Presentation transcript:

Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK

The importance of statistical planning International Conference on Harmonization (ICH) E9 Guideline on Statistical Principles for Clinical Trials

Statistical quality Any high quality trial will include a detailed analysis plan as part of (or an appendix to) the protocol. Statistical quality –Professional competence –Professional responsibility

Pre-specification of the analysis Statistical section of the protocol should include all the principal features of the proposed confirmatory analysis of the primary variable(s) and the way in which anticipated analysis problems will be handled.

Factors Affecting Statistical Methods Used The nature of the variables The number of treatment compared The experimental design Additional factors taken into account for analysis (e.g. baseline)

Failure to define the analysis sets Full analysis set The set of subjects that is as close as possible to the ideal implied by the ITT principle. It is derived from the set of all randomized subjects by minimal and justified elimination of subjects.

Intent to Treat Principle (ITT) The patients data should be analyzed in their assigned treatment group after they have been randomized regardless the treatment they are actual received. Fundamental point –Excluding participants or observed outcomes from analysis and sub-grouping on the basis of outcome or response variables can lead to biased results of unknown magnitude or direction.

Criteria to exclude randomized subjects from full analysis set 1.Failure to satisfy major entry criteria 2.Failure to take at least one does of trial medication 3.The lack of any data post randomization

Per Protocol Set ‘valid cases’, ‘efficacy sample’ or the ‘evaluable subjects’. The set of data generated by the subsets who complied with the protocol sufficiently to ensure that these data would be likely to exhibit the effect of treatment, according to the underlying scientific model.

Criteria of defining Per Protocol Set The completion of a certain pre-specified minimal exposure to the treatment regimen The availability of measurements of the primary variable(s) The absence of any major protocol violations including the violation of entry criteria

An Example: Protocol criteria for patients included in evaluable and ITT analysis Patients who complete all of the visits without violation or major deviations and are at least 80% compliant in taking medication, will be analyzed in the per protocol analysis. All patients taking at least one does of study medication will be included in the intention to treat analysis.

Testing the baseline imbalance This is a common procedure which has no justification in statistical theory Baseline imbalance can not justify the integrity of randomization process. Randomization does not guarantee the balanced of baseline Baseline will be adjusted in the analysis.

Fail to specify the policy on missing values and outliers Imputation techniques to compensate for missing data: –Carry forward of the last observation –Complex mathematical models –Defer detailed policy on irregularity until the blind review of the data at the end of the trial

Blind review The checking and assessment of data during the period of time between trial completion (the last observation on the last subject) and the breaking of the blind, for the purpose of finalizing the planned analysis.

Failure to specify data transformation Transformation (e.g. square root, logarithm) should be specified in the protocol and a rational provided. Especially for the primary variable(s).

Failure to define other derived variables Change from baseline Percentage change from baseline AUC of repeated measures Ratio of two different variables

Excessive emphasis on p-values Confidence Intervals are much more informative Justification for one sided test Type I error Statistical model and the assumptions underlying such models Parametric and non parametric

Failure to consider the adjustment of multiplicity Significance Confidence levels

Multiplicity and Method to Reduce Multiplicity

Inappropriate (or insufficient) use of covariate information Using change from baseline rather than fitting baseline as a covariate. –The inference based on the covariance adjustment is generally more precise than that based on the change adjustment ( Patel (1983,1986) Kenward and Jones (1987) To adjust the main analysis for covariates measured after randomization

Covariant Definition –Efficacy variables or treatment responses are often influenced by or related to factors other than treatment.

Covariant Adjustment Randomization can not guarantee the comparability or the balance of all the covariates especially in smaller studies. In order to obtain a valid and more precise inference of the treatment effect, it is necessary to adjust for covariates that are statistically correlated with the clinical endpoints.

Possible Covariates (Confounding factors, Prognostic factors, risk factors) Demographic –age, gender and race Patient characteristics –disease severity, concomitant medication and medical history Centre in a multicentre study

Data Type and Adjustment Procedure

Failure to model outcomes adequately Treating ordered categorical data in a way that ignores the ordering

Relationship Between Frequency of Caesarian Section(CS) and Maternal Shoe Size

Snoring Behavior in Relation to Presence or Absence of Heart Disease

Fail to reflect the trial structure Carry out a multicentre trial and not fitting centre the centre effect.